Total Raised

$114.26M

Investors Count

28

Deal Terms

2

Funding, Valuation & Revenue

11 Fundings

Mission Bio has raised $114.26M over 11 rounds.

Mission Bio's latest funding round was a Unattributed VC for on August 5, 2025.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

8/5/2025

Unattributed VC

$XXM

0

FY undefined

2

4/1/2022

Angel - II

$XXM

0

FY undefined

1

8/13/2020

Series C

$70M

$XXM

0

FY undefined

7

7/11/2018

Series B

$XXM

$XXM

0

FY undefined

10

12/8/2017

Grant

$XXM

$XXM

0

FY undefined

10

Date

8/5/2025

4/1/2022

8/13/2020

7/11/2018

12/8/2017

Round

Unattributed VC

Angel - II

Series C

Series B

Grant

Amount

$70M

$XXM

$XXM

Investors

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

2

1

7

10

10

Start free trial
New call-to-action

Mission Bio Deal Terms

2 Deal Terms

Mission Bio's deal structure is available for 2 funding rounds, including their Series B from July 11, 2018.

Round

Series B

Series A

Funding Date

$XXM

$XXM

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$XXM

$XXM

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$XXM

$XXM

Board Voting

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$XXM

$XXM

$XXM

$XXM

Series A

$XXM

$XXM

$XXM

$XXM

Mission Bio Investors

28 Investors

Mission Bio has 28 investors. Ally Bridge Group invested in Mission Bio's Unattributed VC funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

8/5/2025

8/5/2025

2
Other Investors, Unattributed VC (2025)

Venture Capital

Hong Kong

4/1/2022

4/1/2022

1
Angel - II

Angel Investor (Group)

California

10/17/2017

8/13/2020

4
Series D, Series A (2017), Series B (2018), Series C (2020)

Venture Capital

California

00/00/0000

00/00/0000

Mayfield

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Alumni Ventures

Subscribe to see more

Venture Capital

New Hampshire

First funding

8/5/2025

4/1/2022

10/17/2017

00/00/0000

00/00/0000

Last Funding

8/5/2025

4/1/2022

8/13/2020

00/00/0000

00/00/0000

Investor

Mayfield

Alumni Ventures

Rounds

2
Other Investors, Unattributed VC (2025)
1
Angel - II
4
Series D, Series A (2017), Series B (2018), Series C (2020)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Angel Investor (Group)

Venture Capital

Venture Capital

Venture Capital

Location

Hong Kong

California

California

California

New Hampshire

New call-to-action

Compare Mission Bio to Competitors

NanoCellect Biomedical

NanoCellect Biomedical specializes in the development and manufacturing of microfluidic cell sorting technology for the biomedical research sector. The company offers a range of cell sorters and accessories designed to enhance precision and maintain high cell viability during sorting processes, suitable for applications in genomics, antibody discovery, and other scientific research areas. NanoCellect's products are utilized by researchers in fields such as stem cell research, plant biology, genomics, antibody discovery, cell line development, and gene editing. NanoCellect Biomedical was formerly known as NanoSort. It was founded in 2009 and is based in San Diego, California.

uFluidix

uFluidix specializes in the custom fabrication of microfluidic devices and chips, operating within the microtechnology industry. The company specializes in manufacturing silicone and thermoplastic components with high precision for various microfluidic applications. uFluidix primarily serves sectors that require advanced microfluidic solutions, such as point-of-care diagnostics, drug delivery, and cancer research. It was founded in 2010 and is based in Toronto, Canada.

Dolomite Microfluidics

Dolomite Microfluidics is involved in the design and manufacture of microfluidic products for applications in biotechnology, chemistry, food and cosmetics, and academic research sectors. The company provides modular systems, components, and solutions for drug encapsulation, droplet manufacture, and particle generation, as well as tools for biological analysis and precision manufacturing of emulsions and foams. Dolomite Microfluidics serves researchers and professionals in the life sciences, materials science, and chemical engineering fields. It was founded in 2005 and is based in Royston, England.

Achira Labs

Achira Labs is a medical technology company specializing in point-of-care testing within the healthcare sector. The company offers a microfluidics-based platform that includes a fluorescence-based reader and integrated microfluidic cartridges, designed to deliver reliable lab-quality results from capillary blood samples. Achira Labs primarily serves the medical diagnostics industry. It was founded in 2009 and is based in Bangalore, India.

Parallel

Parallel Fluidics specializes in microfluidic manufacturing and prototyping within the microfluidics domain. The company produces microfluidic devices using production-grade materials and technologies like transition molding and embedded hardware. Parallel Fluidics serves sectors that require microfluidic technology for research and development, including the biomedical and aerospace industries. It was founded in 2020 and is based in Boston, Massachusetts.

Okomera

Okomera is a company that operates in the cancer care industry. It provides treatment intelligence derived from patient biopsies, utilizing tumor-on-chip technology and AI imaging to inform drug development and clinical decision-making. The company's platform is designed to facilitate testing of treatments, aiming to improve the predictability of preclinical studies and support applications from CRISPR to T-cell potency and drug screening. It was founded in 2020 and is based in Paris, France.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy. By continuing to use this site you are consenting to these choices.